ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Micromet Announces The Publication Of BiTE Antibody Review In Drugs Of The Future
Micromet, Inc.
(Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary
antibodies for the treatment of cancer, inflammation and autoimmune
diseases, announced the publication of a comprehensive review article
entitled, "BiTE: A new class of antibodies that recruit T cells" in the
journal Drugs of the Future. BiTE(R) antibodies are designed to activate
the body's T cells to seek and destroy cancer cells in a tightly controlled
manner.
The review article discusses recently published preclinical and
clinical data on BiTE antibodies, which are evolving into a new class of
antibody-based therapeutics, with several new members in various stages of
development. One emphasis is on CD19-specific BiTE antibody MT103 (also
known as MEDI-538), which produced complete and partial responses at
generally well tolerated and very low doses in late-stage lymphoma
patients. Another emphasis is on several preclinical studies showing
significant anti-tumor activity of three other BiTE antibodies targeting
solid tumors by EpCAM (CD326), EphA2 or CEA antigens. All three
tumor-associated antigens are found on many solid tumors. In addition, the
article provides a detailed description of the mode of action of BiTE
antibodies, comparing it to natural T-cell responses.
"Our latest review article demonstrates the clinical progress and high
level of scientific understanding the company has acquired in numerous
published studies about its proprietary BiTE antibody technology,"
commented Patrick A. Baeuerle, Micromet's chief scientific officer. "BiTE
antibodies represent a novel platform of clinically-validated,
antibody-based therapeutics for the treatment of a wide range of cancers."
About BiTE(R) Antibodies
BiTE(R) antibodies are designed to direct the body's cytotoxic, or
cell- destroying, T cells against tumor cells, and represent a new
therapeutic approach to cancer therapy. BiTE antibodies have been shown to
induce an immunological synapse between a T cell and a tumor cell in the
same manner as observed during physiological T cell attacks. These
cytolytic synapses enable the delivery of cytotoxic proteins from T cells
into tumor cells, ultimately inducing a self-destruction process in the
tumor cell referred to as "apoptosis," or programmed cell death. In the
presence of BiTE antibodies, T cells have been demonstrated to serially
eliminate tumor cells, which explains the activity of BiTE antibodies at
very low concentrations and at very low ratios of T cells to target tumor
cells. Through the process of killing cancer cells, T cells proliferate,
which leads to an increased number of T cells at the site of attack.
Several antibodies in Micromet's product pipeline are BiTE antibodies
and have been generated based on Micromet's proprietary BiTE product
development platform. The most advanced BiTE antibody is MT103 (MEDI-538)
targeting CD19, and is being tested in a phase 2 clinical trial in acute
lymphoblastic leukaemia patients and in an ongoing phase 1 clinical study
in advanced non- Hodgkin's lymphoma patients. Three other BiTE antibodies,
targeting EpCAM (CD326), CEA and MCSP, are in pre-clinical development.
BiTE is a registered trademark of Micromet.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company developing novel,
proprietary antibodies for the treatment of cancer, inflammation and
autoimmune diseases. Three of its antibodies are in clinical development.
MT103 (MEDI-538), the first antibody in Micromet's product pipeline
developed utilizing the BiTE(R) antibody technology platform, is being
evaluated in a phase 2 clinical trial for the treatment of patients with
acute lymphoblastic leukemia, and in a phase 1 clinical trial for the
treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies
represent a new class of therapeutic antibodies that activate a patient's
own cytotoxic T cells to eliminate cancer cells. Micromet is developing
MT103 in collaboration with MedImmune, a subsidiary of Astra Zeneca plc.
The second clinical stage antibody is adecatumumab (MT201), a human
monoclonal antibody targeting EpCAM expressing tumors. Adecatumumab is
being developed by Micromet in collaboration with Merck Serono in a phase
1b clinical trial evaluating adecatumumab in combination with docetaxel for
the treatment of patients with metastatic breast cancer. The third clinical
stage antibody is MT293 (formerly D93), also known as TRC093, a
first-in-class humanized monoclonal antibody that inhibits angiogenesis and
tumor cell growth by binding cleaved collagen. MT293, which is currently
being tested in a phase 1 clinical trial, is licensed to TRACON
Pharmaceuticals, Inc. and is being developed for the treatment of patients
with cancer and age-related macular degeneration. In addition, Micromet has
established a collaboration with Nycomed for the development and
commercialization of MT203, Micromet's human antibody neutralizing the
activity of granulocyte/macrophage colony stimulating factor (GM-CSF),
which has potential applications in the treatment of various inflammatory
and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or
multiple sclerosis.
Forward Looking Statements
This release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. Factors that may cause actual
results to differ materially from any future results expressed or implied
by any forward-looking statements include the risk that product candidates
that appeared promising in early research, preclinical studies or clinical
trials do not demonstrate safety and/or efficacy in subsequent clinical
trials, the risk that encouraging results from early research, preclinical
studies or clinical trials may not be confirmed upon further analysis of
the detailed results of such research, preclinical study or clinical trial,
the risk that additional information relating to the safety, efficacy or
tolerability of our product candidates may be discovered upon further
analysis of preclinical or clinical trial data, the risk that we or our
collaborators will not obtain approval to market our product candidates,
the risks associated with reliance on outside financing to meet capital
requirements, and the risks associated with reliance on collaborators,
including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or
conduct of further development and commercialization activities relating to
our product candidates. You are urged to consider statements that include
the words "ongoing", "may", "will", "would", "could", "should", "believes",
"estimates", "projects", "potential", "expects", "suggests", "plans",
"anticipates", "intends", "continues", "forecast", "designed", "goal", or
the negative of those words or other comparable words to be uncertain and
forward-looking. These factors and others are more fully discussed in our
periodic reports and other filings with the SEC.
Any forward-looking statements are made pursuant to Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, and, as such, speak only as of the date
made. Micromet, Inc. undertakes no obligation to publicly update any
forward-looking statements, whether as a result of new information, future
events or otherwise.
Reference
(1) Baeuerle PA, Reinhardt C, and Kufer B (2008). BiTE: A new class of antibodies that recruit T cells. Drugs Future, 2008, in press.
Micromet, Inc.
http://www.micromet-inc.com
Micromet anunþã publicarea de muºcãturã de examinare de anticorpi de droguri în viitor - Micromet Announces The Publication Of BiTE Antibody Review In Drugs Of The Future - articole medicale engleza - startsanatate